niacinamide has been researched along with Neurofibroma, Plexiform in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Neurofibroma, Plexiform: A type of neurofibroma manifesting as a diffuse overgrowth of subcutaneous tissue, usually involving the face, scalp, neck, and chest but occasionally occurring in the abdomen or pelvis. The tumors tend to progress, and may extend along nerve roots to eventually involve the spinal roots and spinal cord. This process is almost always a manifestation of NEUROFIBROMATOSIS 1. (From Adams et al., Principles of Neurology, 6th ed, p1016; J Pediatr 1997 Nov;131(5):678-82)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib was administered orally twice daily for consecutive 28-day cycles." | 2.78 | Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. ( Balis, FM; Choyke, PL; Dombi, E; Fox, E; Jayaprakash, N; Kim, A; Korf, B; Martin, S; Muradyan, N; Reddy, A; Tepas, K; Turkbey, B; Widemann, BC; Wolters, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, J | 1 |
| Dombi, E | 2 |
| Jousma, E | 1 |
| Scott Dunn, R | 1 |
| Lindquist, D | 1 |
| Schnell, BM | 1 |
| Kim, MO | 1 |
| Kim, A | 2 |
| Widemann, BC | 2 |
| Cripe, TP | 1 |
| Ratner, N | 1 |
| Tepas, K | 1 |
| Fox, E | 1 |
| Martin, S | 1 |
| Wolters, P | 1 |
| Balis, FM | 1 |
| Jayaprakash, N | 1 |
| Turkbey, B | 1 |
| Muradyan, N | 1 |
| Choyke, PL | 1 |
| Reddy, A | 1 |
| Korf, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)[NCT03231306] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-11-28 | Active, not recruiting | ||
| Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden[NCT05238909] | 200 participants (Anticipated) | Observational [Patient Registry] | 2022-03-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Neurofibroma, Plexiform
| Article | Year |
|---|---|
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Maximum Tolerated | 2013 |
1 other study available for niacinamide and Neurofibroma, Plexiform
| Article | Year |
|---|---|
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Proliferation; Chromatogr | 2012 |
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Proliferation; Chromatogr | 2012 |
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Proliferation; Chromatogr | 2012 |
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Proliferation; Chromatogr | 2012 |